Skip to main content
Sign In
 

Tobias Eckle, MD, PhD

Associate Professor


  • Professional Activities
  • Research Interests
  • Publiciations
  • Education:

    M.D., Eberhard-Karls University, Tübingen, Germany, 2001

    Ph.D., Eberhard-Karls University, Tübingen, Germany, 2001



    Professional Experience:

    2010 - Present, Associate Professor, Department of Anesthesiology, University of Colorado Denver

    2008 - Present, Director, Resident Training in Basic Science Research, University of Colorado Denver

    2007 - 2008, Assistant Professor, Department of Anesthesiology, University Hospital of Tübingen

    2006 - 2007, Clinical Fellow, Critical Care Medicine, University Hospital of Tübingen Germany

    2005 - 2006, Post Doctoral Fellowship, Department of Anesthesiology, University Hospital of Tübingen



    Current Research Support:

    K08 HL102267 (PI: Eckle)

    05/07/2010 – 04/30/2015

    NIH-NHLBI

    Period in Cardioprotection
    This grant application proposes to target circadian rhythm proteins – particularly period-2 – in cardioprotection from ischemia. Specifically, period-2 mediates a metabolic switch from aerobic metabolism to anaerobic glycolysis in myocytes.

    Research Statement

    I am a physician scientist trained in anesthesiology, critical care medicine and cell biology. My research group is particularly interested in identifying cellular adaptive mechanisms to ischemia and hypoxia. During my postdoctoral fellowship, I established animal models of acute lung injury, myocardial ischemia and whole body hypoxia. Based on the huge variety of molecular biology techniques combined with a profound knowledge of sophisticated animal models, I offer unique training opportunities and thus successfully trained medical students, post docs, fellows and faculty within the last decade. Results from my current work have led to the identification of novel genes and new therapeutic concepts in the treatment of myocardial ischemia.

    Selected Publiciations

    Eckle T., Prix L., Jahn G., Klingebiel T., Handgretinger R., Selle B., Hamprecht K. 2000. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:3286-9.

    Eckle T., Lang P, Prix L., Jahn G., Klingebiel T., Handgretinger H., Selle B., Niethammer D., Hamprecht K. 2002. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant 30:433-9

    Eckle T., Jahn G., Hamprecht K. 2003. High Impact of an Expanded Restriction Fragment Length Polymorphism Assay on Detection of Ganciclovir-Resistant UL97 Mutants of Human Cytomegalovirus. Antimicrob Agents Chemother 47:442-3.

    Eckle T., Jahn G., Hamprecht K. 2004.The influence of mixed HCMV UL 97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. J Clin Virol 30:50-6.

    Eckle, T., A. Grenz, D. Kohler, A. Redel, M. Falk, B. Rolauffs, H. Osswald, F. Kehl, and H.K. Eltzschig. 2006. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol 291:H2533-40.

    Eckle, T., L. Fullbier, M. Wehrmann, J. Khoury, M. Mittelbronn, J. Ibla, P. Rosenberger, and H.K. Eltzschig. 2007. Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury. J Immunol 178:8127-8137.

    Eckle, T., T. Krahn, A. Grenz, D. Kohler, M. Mittelbronn, C. Ledent, M.A. Jacobson, H. Osswald, L.F. Thompson, K. Unertl, and H.K. Eltzschig. 2007. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115:1581-1590.

    Eckle, T., D. Kohler, M. Faigle, A. Grenz, M. Mittelbronn, S. Laucher, M.L. Hart, S.C. Robson, C.E. Muller, and H.K. Eltzschig. 2007. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116:1784-1794.

    Eckle, T, Faigle M, Grenz A, Laucher S, Thompson L and Eltzschig HK. 2008. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111:2024-35.

    Eckle T, Fuellbier L, Grenz, A and Eltzschig HK. 2008. Usefulness of pressure controlled ventilation at high inspiratory pressures to induce acute lung injury in mice. Am J Physiol Lung Cell Mol Physiol 295:L718-24.

    Eckle, T., D. Kohler, R. Lehmann, K.C. El Kasmi, and H.K. Eltzschig. 2008. Hypoxia Inducible Factor (HIF)-1 Is Central to Cardioprotection: A New Paradigm for Ischemic Preconditioning. Circulation 118:166- 75

    Eckle T, Grenz, A, Laucher S, and Eltzschig HK. 2008. A2B adenosine receptor attenuates ventilator induced lung injury by enhancing alveolar fluid clearance. Journal of Clinical Investigation 118:3301-15.

    Eltzschig HK, Kohler D, Eckle T, Kong T, Robson S, and Colgan SP. 2009. Central role of Sp1-regulated CD39 in hypoxia / ischemia protection. Blood 113:224-32.

    Eckle T, Koeppen M, Eltzschig HK. 2009. Selective Deletion of the A1 Adenosine Receptor Abolishes Heart-Rate Slowing Effects of Intravascular Adenosine in vivo. PLoS ONE. 4(8):e6784.

    Eckle T, Koeppen M, Eltzschig HK. 2009. Role of Extracellular Adenosine in Acute Lung Injury. Physiology. 24:298-306